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Abstract  
Background: Free light chains (FLCs) have a range of biological functions and may act as a broad 
marker of immune suppression and activation and inflammation. Measurement of salivary FLCs 
may provide practical advantages in a range of clinical populations. The aim of the present study 
was to develop normal reference ranges of FLCs in saliva and assess the effects of acute exercise 
on FLC levels in younger and older adults.  
Methods:  Saliva FLC concentrations and secretion rates were measured in young (n = 88, aged 
18–36) and older (n = 53, aged 60–80) adults. To assess FLC changes in response to acute 
exercise, young adults completed a constant work-rate cycling exercise trial at 60% VO2max (n = 
18) or a 1 h cycling time trial (TT) (n = 10) and older adults completed an incremental submaximal 
treadmill walking exercise test to 75% HRmax (n = 53). Serum FLCs were measured at baseline and 
in response to exercise.  
Results: Older adults demonstrated significantly higher levels of salivary FLC parameters 
compared with young adults. Median (5–95th percentile) concentrations were 0.45 (0.004–3.45) 
mg/L for kappa and 0.30 (0.08–1.54) mg/L for lambda in young adults; 3.91 (0.75–19.65) mg/L for 
kappa and 1.00 (0.02–4.50) mg/L for lambda in older adults. Overall median concentrations of 
salivary kappa and lambda FLCs were 10-fold and 20-fold lower than serum, respectively. 
Reductions in salivary FLC concentrations and secretion rates were observed immediately post- 
and at 1 h post exercise, but were only significant for the older cohort; FLCs began to recover 
between post and 1 h post-exercise. No changes in serum FLCs were observed in response to 
exercise.  
Conclusions: The ability to assess FLCs in saliva and the reference ranges provided will likely 
broaden the use of this biomarker in healthy and clinical populations. The elevated salivary FLCs in 
older adults may relate to a deterioration of oral health and be important in the context of 
inflammatory processes and diseases associated with ageing. Exercise did not affect serum FLCs, 
but reduced salivary FLCs, most notably in older adults, which may reflect reduced transport of 
FLCs from serum into saliva.  
Key words: Free light chains, saliva, serum, age, exercise  
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INTRODUCTION  
Introduction to free light chains and their production in healthy individuals  
Immunoglobulins are produced by plasma cells and comprise two identical heavy chains and two 
identical light chains, which can be either kappa or lambda isotypes.  During the process of 
immunoglobulin synthesis, surplus light chains are produced at a rate of 40% above heavy chains  
(1).  These excess light chains that do not form whole immunoglobulins, known as free light chains 
(FLCs), are released into the circulation. In healthy individuals approximately 500 mg of FLCs are 
produced each day, with kappa production outweighing lambda by a ratio of 2:1.  In a healthy 
state, serum FLC reference ranges are 3.3–19.4 mg/L for kappa and 3.7–26.3 mg/L for lambda (2).  
These reference ranges are based on the first FLC assay developed ten years ago, and new 
methods for FLC quantitation are now available, leading to a slightly broader range (1.2–55.2 
mg/L) in values reported for healthy individuals (3).  FLCs are metabolised by the kidneys where 
up to 10–30 g of FLC can be processed per day (4).  Lambda FLCs are cleared from the circulation 
at a slower rate than kappa FLCs; consequently, the ratio of kappa to lambda FLC (FLC ratio) in 
serum is healthy individuals is between 0.26–1.65 (2).  The short half-life of FLCs in serum (2–4 
hours for kappa and 3–6 hours for lambda) compared with whole immunoglobulins (5–8 days for 
IgA and IgM and 20 days for IgG) enables real time monitoring of immune suppression and 
stimulation, or disease progression and responses to treatment in conditions involving FLC 
dysregulation (5, 6).  
Free light chains as a biomarker in clinical populations  
FLCs have become a key haematological biomarker in the diagnosis and monitoring of plasma cell 
disorders. In these conditions, monoclonal light chains are secreted due to clonal plasma cell 
proliferation, usually resulting in overproduction of one type of light chain and subsequently a 
perturbed FLC ratio.  The use of serum FLC analysis is recommended internationally for the 
screening, prognosis and monitoring of multiple myeloma (7, 8).  Serum FLCs are also used in the 
identification and prognostication in a range of other related disorders including pre-myeloma 
states, such as the non-malignant precursor to myeloma (monoclonal gammopathy of 
undetermined significance), smouldering myeloma and solitary bone plasmacytoma; and other 
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haematological conditions, including chronic lymphocytic leukaemia, non-Hodgkin lymphoma, 
Waldenstrom’s macroglobulinaemia and AL amyloidosis (6, 8, 9).  In plasma cell disorders such as 
myeloma, the FLC ratio is a key marker for diagnosis, prognosticating and monitoring and the 
monoclonal light chain level or the difference between the monoclonal light chain and uninvolved 
light chain is also employed for monitoring over time (10, 11).   
Serum FLC measurement has been proven to be important in non-malignant disorders where 
polyclonal FLCs can be used as a broad marker of immune activation, inflammation and infection.  
Increases in FLCs have been noted in a range of diseases including: rheumatoid arthritis, multiple 
sclerosis, systemic lupus erythematosus, heart failure, diabetes, renal disease, asthma, chronic 
obstructive pulmonary disease, inflammatory bowel disease and HIV infection (3, 12, 13).  Data 
from these studies suggest that FLCs are useful as a marker of severity and or risk for certain 
diseases, monitoring disease activity and potentially predicting disease progression. In conditions 
relating to polyclonal light chains, both kappa and lambda FLCs typically increase, resulting in 
minimal or no change in the FLC ratio.  In chronic kidney disease, the FLC ratio increases with 
reference ranges of 0.37–3.1 reported in these individuals (14).  This is due to an alternative 
pathway of clearance being used with renal impairment, resulting in similar serum half-lives of 
kappa and lambda.  As kidney function declines, the ratio becomes further biased towards kappa, 
as a result of greater production relative to lambda, but similar clearance time (14).  
Free light chains as a biomarker in the general population  
The use of FLCs as a biomarker in non-clinical populations has attracted attention in recent years 
due to a pivotal study by Dispenzieri (15).  In a large longitudinal data set of individuals aged ≥ 50 
years without plasma cell disorders, the sum of kappa and lambda FLCs (FLC sum) negatively 
predicted survival. In this sample of the general population, those with the highest FLC sum levels 
had an increased risk of all-cause mortality.  This increased risk of death remained at 2:1 after 
controlling for age, sex and renal insufficiency.  Higher activation of the immune system and 
inflammatory markers relate to cardiovascular and cancer deaths; however, the exact mechanism 
linking polyclonal light chains with mortality risk is unknown, as is the extent to which the 
relationship is causal or correlational (10).  
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Biological role of free light chains  
The diverse biological functions of FLCs have been highlighted in several publications, reviewed in 
detail elsewhere (3, 12).  FLCs have been shown to interact with neutrophils and mast cells, which 
are both involved in inflammatory processes.  Neutrophil apoptosis has been shown to be inhibited 
by FLCs (16) and FLCs can also bind to neutrophils and stimulate release of IL-8 (17), a pro-
inflammatory chemokine that promotes neutrophil migration.  FLCs have been implicated in the 
activation of mast cells to induce allergic responses (3).  Due to their ability to bind to monocytes, 
which are antigen presenting cells, FLCs have been suggested to offer an alternative pathway to 
support antigen uptake and assist the related immune response (12, 18).  Due to these activities, 
FLCs have been proposed to stimulate chronic inflammation via activation of specific immune cells 
(19).  This mechanism would account for the numerous relationships observed between FLCs and 
inflammatory and autoimmune diseases.  Other evidence suggests that FLCs could also have 
beneficial effects; administration of FLCs have also been shown to be anti-inflammatory and also 
have anti-viral properties in the context of viral myocarditis (20).  
 
Free light chains and exercise  
 
It has been hypothesised that acute exercise could affect FLCs via immune activation.  Kappa 
FLCs have been shown to be significantly elevated in runners following a marathon compared with 
pre-exercise levels. No accompanying change in lambda FLCs was observed, as such some 
participants experienced an abnormal increase in the FLC ratio after exercise (21).  The authors 
suggested these changes may be due to acute reductions in renal function with prolonged 
exercise, or alternatively due to immune stimulation or immunoglobulin redistribution.  In elderly 
individuals, endurance walking over a period of 4 days did not significantly affect serum FLC levels 
(22).  It may be that the nature of this exercise, being of relatively low intensity, was not a 
significant stimulus to elicit immune changes or alternatively impact upon renal function and 
subsequently FLC clearance.  To our knowledge, no other investigations into the effects of 
exercise on FLCs have been conducted.  Given the role of FLCs in immune and inflammatory 
processes, FLCs could be a useful marker of inflammation in relation to not only acute exercise but 
also exercise or physical activity interventions; they could also serve as a potential future marker of 
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infection risk or overtraining.  Thus, further studies are warranted in order to understand the 
relationship between exercise and FLCs and their utility in exercise immunology research.   
Potential of free light chains as a salivary biomarker  
The advantages of saliva testing have been well established in biomarker research. For example, 
non-invasive measurement may be more appropriate for repeated measures, long term sampling, 
or for certain populations or study designs where blood sampling may not be feasible.  The broad 
value of FLCs in a range of diseases and the general population make them a suitable candidate 
for translation into salivary measurement.  As the constituents of serum are capable of contributing 
to the oral environment, salivary FLCs may reflect systemic levels thus could also provide an 
insight into local immune activation and inflammation.  However, the relationship between FLCs in 
serum and saliva has yet to be explored.  
Salivary FLCs may offer a convenient and accessible method of identifying elevated levels of 
polyclonal light chain production and monitoring FLCs over time in various diseases and the wider 
population.  However, to date, an assay sensitive enough to detect FLCs in saliva has not been 
available. We have recently developed assays that sensitively and reliably detect very low levels of 
kappa and lambda FLCs (< 0.01 mg/L), appropriate for use in saliva.  In order to investigate their 
potential as a future biomarker, normal reference ranges of salivary FLCs need to be established 
across a range of ages.  The aim of the present study, therefore, was to develop normal ranges of 
FLCs in saliva in healthy individuals of different ages and assess the relationship between FLCs in 
saliva and serum.  Secondly, this study sought to define how salivary and serum FLCs respond to 
exercise and if this varies in relation to age.  
 
METHODS 
 
 
Participants  
 
Four separate cohorts (N =141) of participants were used as part of this investigation: 3 groups of 
young adults (aged ≤ 36 years) and 1 group of older adults (aged ≥ 60 years).  
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Cohort 1: Healthy young adults (n = 60, 35 males) with a mean ± SD age of 26.2 ± 3.7 years  
donated a saliva sample to inform saliva FLC reference ranges among this age group.  
Cohort 2: Young men (n = 18, aged 22.9 years ± 3.4 years) who engaged in regular sports training 
(maximal oxygen uptake, VO2max = 55.8 ± 13.6 mL/kg/min) participated in an acute bout of 
submaximal exercise.  Participants were included if they participated in at least 3 sports training 
sessions per week and  ≥ 3 h of total moderate/high-intensity training per week. Their self-reported 
training loads (determined by a pre-screening questionnaire) averaged 12 ± 5 h/week.  
Cohort 3: Trained male cyclists (n = 10) with a competitive cycling background of at least 3 years 
(VO2max = 73.1 ± 4.7 mL/kg/min), participated in an acute bout of intense exercise before and after 
a period of intensified training.  Athletes were cycling ≥ 3 times per week for a minimum of 2 h/day 
and reported a mean training load of 9.3 ± 2.4 h/week.  
Key inclusion criteria for cohorts 1–3 were no chronic illness or history of chronic illness,  
Cohort 4: Older adults (n = 53, 32 males) with aged 67.2 ± 4.9 years participated in an acute bout 
of submaximal exercise.  Their VO2max was 37.8 ± 9.84 mL/kg/min, predicted based on heart rate 
(HR) and VO2 during submaximal exercise.  Twenty percent of participants reported suffering from 
a chronic illness, which were hypertension and asthma, and 38% reported taking medication, such 
as antihypertensives, non-corticosteroid inhalers, statins and gastrointestinal medications.  
Participants were excluded if suffering from any immune or endocrine disorder or any condition 
that precluded them from exercise.  For all cohorts, inclusion criteria stipulated that participants 
were not suffering from any acute illness in the two weeks prior to, or during the study. 
 
 
Baseline reference ranges of free light chains in saliva in healthy adults  
 
To establish reference ranges for FLC in saliva in relation to age, baseline saliva levels from 
cohorts 1–3 were pooled to form a ‘younger’ cohort and cohort 4 was used for reference ranges in 
‘older’ adults.  A subset of 38 young adults (from cohorts 1 and 3) and 40 older adults (from cohort 
4) had serum samples available to compare systemic concentrations of FLCs in serum with 
salivary levels.  Again, all serum samples were taken under resting conditions prior to any 
exercise.  
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FLC response to exercise in young and older adults: exercise protocols  
 
Cohort 2: Approximately 1 week before the acute exercise trial, participants completed a 
continuous incremental test on an electromagnetically braked cycle ergometer (Lode Excalibur 
Sport, Groningen, Netherlands) to volitional exhaustion to determine their VO2max. Expired gas 
samples were collected in Douglas bags (Harvard Apparatus, Edenbridge, UK) during the final 
minute of each work-rate increment, and HR was measured continuously using short-range radio 
telemetry (Polar, Kempele, Finland).  An oxygen/carbon dioxide analyzer (Servomex 1400, 
Crowbridge, UK) was used along with a dry gas meter (Harvard Apparatus, Edenbridge, UK) to 
determine VE, VO2, and VCO2. From the VO2–work-rate relationship, the work-rate equivalent to 
60% VO2max was determined.  After a 15 min recovery, participants cycled for 20 min at a steady 
state work rate equivalent to 60% VO2max with expired gas samples collected after 10 and 20 min in 
order to ensure that the calculated work rate elicited the desired VO2.  For the acute submaximal 
exercise trial, participants arrived at 12:00 following a 3 h fast. A saliva sample was collected then 
participants cycled for 2 h at 60% VO2max on a stationary cycle ergometer.  Immediately after 
completing the exercise and also 1 h post-exercise saliva samples were again collected.   
 
Cohort 3: Participants visited the laboratory for pre-trial exercise testing to confirm suitability to 
participate.  During this visit, participants underwent an incremental cycle test to exhaustion on an 
electronically braked ergometer (Lode Excalibur Sport, Groningen, Netherlands).  Expiratory gases 
were collected continually throughout the test and breath-by-breath analysis was performed 
automatically with a Moxus metabolic systems analyser (AEI Technologies Inc., Naperville, IL, 
USA).  Heart rate was recorded continually using short range telemetry (Polar RS800CX, Polar, 
Kempele, Finland).  Participants had to achieve a VO2max of ≥65 mL/kg/min to be included in the 
study.  
On the day of the acute exercise bout, participants arrived at the laboratory between 06:30–8:30 
following an overnight fast of ≥ 8 h.  Blood samples were collected followed by a saliva sample. 
After a 10-min warm up, participants performed an all-out 1 h time trial (TT) on their own bicycles 
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on a turbo trainer (CycleOps Flow).  Heart rate was recorded continually during the TT with short 
range telemetry (Suunto). Participants were blinded from their power, cadence and HR during the 
TT and were only provided with a stop clock to monitor time.  Post-TT blood and saliva samples 
were collected within 5 min of exercise cessation.  
Cohort 4: Participants arrived to the laboratory between 08:00 and 09:00 where they were fitted 
with a HR monitor (Polar, Electro Kempele, Finland).  They were then familiarised with the 
procedure for collection of expired gas using Douglas bags.  They then rested for 15 min before a 
blood sample was taken followed by saliva sample collection.  Participants then completed an 
acute bout of exercise in the form of an incremental submaximal treadmill test. Participants began 
walking on the treadmill and speed was gradually increased until the participant reached a pace 
they considered ‘brisk walking’. The gradient was increased every 4 min and during the final min of 
each stage expired gas samples were collected into Douglas bags (Cranlea, Birmingham, UK). HR 
was monitored continuously throughout the exercise and the test was terminated once the 
participant had reached 75% of their predicted maximum HR, as determined by the formula: 208-
(age×0.7) (23).  A blood and saliva sample was taken immediately after exercise and 1 h post-
exercise. VCO2 and VO2 were determined using O2/CO2 analyser (Servomex 1440, Crowborough, 
UK) and expired gas volumes were measured using a dry gas meter (Harvard Apparatus, 
Edenbridge, UK).  Using a regression equation created from plotting the relationship between HR 
and VO2 during the final three stages of exercise, VO2max was predicted.  
 
Saliva sample collection and analyses  
Saliva samples were collected using the same technique across cohorts. Unstimulated whole 
saliva samples were collected by passive dribble into pre-weighed tubes for a timed period of 2–4 
min.  Saliva volume was calculated by re-weighing the tube post-collection assuming a density of 
1g/mL. Saliva flow rates (mL/min) were determined by dividing the volume of saliva by the 
collection time.  Samples were centrifuged to separate cells and insoluble matter and the 
supernatant was removed and stored at –20°C until assay.  
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Salivary kappa and lambda FLCs were quantified using highly sensitive sandwich ELISAs 
developed by the Clinical Immunology Service at the University of Birmingham.  These assays use 
monoclonal antibodies (mAbs) that have been characterised and validated previously (24).  The 
microtitre wells were coated with mAbs that specifically target either human kappa or lambda FLC 
and thus do not bind light chain in whole immunoglobulin (Abingdon Health, York, UK).  After a 
blocking period of 1 h to prevent non-specific binding, standards, controls and saliva samples were 
added to the plate in duplicate. After 1 h incubation, plates were washed to remove any unbound 
sample.  Kappa or lambda detection antibody labelled with horseradish peroxidase was then 
added to the plate and left to incubate for 1 h. Detection antibodies were mAbs specific for kappa 
or lambda light chains either free or bound, that recognise an epitope distinct from the one used to 
capture the FLCs from saliva (Abingdon Health, York, UK). Plates were washed again and 
substrate solution was added; after 10 min incubation, the reaction was stopped and the optical 
density was measured at 450 nm.  The intra-assay CVs were 9.9% for kappa and 6.7% for lambda 
and inter-assay CVs were 15.3% for kappa and 16.4% for lambda.  The limits of detection were 
calculated by serially diluting normal serum 1 in 2 in assay buffer and selecting the lowest 
concentration determined by the assays above the blank (well containing only assay buffer).  Limits 
were 0.004 mg/L and 0.001 mg/L for kappa and lambda FLCs, respectively.  The calibration 
ranges used in the assay were 0.00028–2.82 mg/L for kappa and 0.0003–2.96 mg/L for lambda; 
saliva samples were diluted 1 in 15 with 0.01M phosphate buffered saline.  
 
Serum sample collection and analyses  
 
Venous blood was collected from an antecubital vein into plain tubes (BD Vacutainer, 
Plymouth, UK).  Blood was allowed to clot at room temperature before being centrifuged and  
the separated serum was stored at −20°C until analysis.  Serum kappa and lambda FLCs were 
quantified using a multi-plex bead-based assay using a Luminex platform (Bio-plex systems, 
BioRad Laboratories, California, USA).  This assay was developed by the Clinical Immunology 
Service at the University of Birmingham and uses mAbs specific for either kappa or lambda FLC in 
a competitive inhibition format.  Both intra- and inter-assay CVs were < 10%. Full details for this 
assay have been described previously (24).   
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Free light chain parameters  
 
A range of FLC parameter outputs were analysed as part of this study.  In addition to 
concentrations of kappa and lambda FLC, the ratio of kappa to lambda FLC (Κ:λ ratio) and the 
difference between kappa and lambda FLC (FLC difference) were examined.  The Κ:λ ratio and 
FLC difference are classically used in conditions involving perturbed levels of FLC, such as plasma 
cell disorders (11, 25).  The sum of kappa and lambda FLCs (FLC sum) was also investigated as 
this measure has been employed in the general population in relation to non-clonal light chains 
(15).  As this study is the first comprehensive investigation into FLC in saliva, all the above 
parameters were included to compare saliva to conventional serum markers and enable any future 
comparisons between healthy and clinical populations.  In addition to concentrations, saliva 
secretion rates of immunoglobulins are typically reported to reflect the total availability of protein at 
the oral surface and control for hydration status (26).  Secretion rates of FLCs (µg/min) were 
calculated as saliva flow rate x kappa/lambda concentration.  The other parameters, sum, 
difference and ratio, were also additionally expressed in this way to control for any impact of flow 
rate upon these variables.  
 
 
Statistical analyses  
 
Analyses were undertaken using IBM SPSS version 21.  Univariate ANOVA was used to examine 
differences between young and older age groups for all saliva and serum FLC parameters.  As 
certain medications can impact upon salivary flow rate regulation (27, 28), subsequent univariate 
ANCOVA was then performed for saliva variables to control for any confounding effects of chronic 
medication usage in relation to age and FLC parameters.  Spearman’s rank correlation was used 
to assess the relationship between FLC parameters in serum and saliva.  Correlational analyses 
were carried out for the study cohort as a whole and separately within young and older age groups.  
                                                                                                                                                         
For cohorts 2–4, repeated measures ANOVA was used to analyse FLC responses to exercise.  
When significant main effects of time were observed, Bonferroni post-hoc tests were applied. For 
these exercise studies, percentage change in FLC concentration/secretion rates between pre- and 
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post- exercise time points were calculated and compared across studies using univariate ANOVA.  
If data were not normally distributed, statistical analysis was performed on the logarithmic 
transformation of the data.  As data was generally skewed, and to provide information regarding 
the full spread of data, tables report medians along with 5–95th percentiles; for analyses of smaller 
groups (cohorts 2 and 3) full ranges are reported.  Greenhouse-Geisser corrected F values are 
reported for repeated measures analyses and partial η2, a measure of effect size, is reported 
throughout. 
 
RESULTS 
Ranges of free light chains in healthy young and older adults  
Participant characteristics and FLC parameters in serum and saliva in relation to age are reported 
in Table 1.  Saliva flow rates were significantly higher in young adults compared to older adults. 
Older adults demonstrated significantly higher levels of both kappa and lambda FLCs in saliva; 
consequently, older adults exhibited higher FLC sum values.  Older adults also registered a 
significantly higher κ:λ ratio and FLC difference as a result of higher kappa FLC levels relative to 
lambda in older individuals.  When examining saliva parameters expressed as secretion rates, 
significant age differences were again observed for all saliva parameters: kappa and lambda 
secretion rates, FLC sum, FLC difference and the κ:λ ratio.  Age differences between kappa and 
lambda secretion rates and the κ:λ ratio controlling for flow rate are illustrated in Figure 1.  In 
serum, there was no significant difference between age groups for kappa FLCs. However, lambda 
levels were significantly higher in young adults, resulting in a significantly lower κ:λ ratio and 
greater FLC difference compared with the older adults.  Statistics for age group differences for 
serum and saliva are reported in Table 1.   
In the study population as a whole, in comparison to saliva, the median concentrations of FLCs in 
serum were over 10-fold greater for kappa and 20-fold greater for lambda. A significant positive 
correlation was present between serum and saliva for the κ:λ ratio, rs(76) = 0.33, p = 0.004, and 
FLC difference, rs(76) = 0.40, p < 0.001.  No significant correlations emerged between serum and 
saliva for kappa or lambda FLC concentrations, the FLC sum, nor serum concentrations and saliva 
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secretion rates.  Further, there were no significant relationships for serum and saliva FLCs within 
age groups.  
Free light chain parameters controlling for potential confounding variables  
None of the younger adults reported taking any on-going medication whereas twenty older adults 
(38%) reported taking chronic medication.  All age x saliva parameter findings withstood 
adjustment for medication use, with p values all remaining ≤ 0.001 with the exception of flow rate 
(p = 0.002) and lambda secretion rate (p = 0.009).  Similarly, all age x serum findings remained 
significant at the 0.01 level when controlling for medication use.  No sex or sex by age group 
interactions were observed for any saliva or serum parameters.   
 
FLC responses to acute exercise in young and older adult populations 
I. The effects of 2 h cycling at 60% VO2max on salivary free light chains in healthy exercise-trained 
young men  
Table 2 describes the salivary FLC responses to acute exercise in cohort 2.  In general, saliva 
parameters were reduced post-exercise, and then recovered at 1 h post-exercise. However, no 
significant effect of exercise was observed for flow rate, kappa or lambda concentration and FLC 
sum.  For the FLC difference and Κ:λ ratio, significant effects of time were observed, F(2,34) = 
3.98,  p = 0.031, η2 = 0.190 and F(2,34) = 4.84,  p = 0.015, η2 = 0.221, respectively.  These indices 
increased at 1 h post-exercise in comparison to immediately post-exercise.   
These results were replicated when examining FLCs controlling for flow rate, with FLC difference 
(F(2, 34) = 4.01,  p = 0.035, η2 = 0.191) and Κ:λ ratio (F(2, 34) = 7.96,  p = 0.002, η2 = 0.319) 
producing significantly higher results at 1 h compared with immediately post-exercise.  Kappa and 
lambda secretion rates and FLC sum did not exhibit any significant changes in response to 
exercise.  Percentage changes in FLC concentrations and secretion rates in response to exercise 
are shown in Table 5.  
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II. The effects of a 1 h all-out cycling time trial on free light chains in trained young male cyclists  
Saliva  
Overall, saliva variables registered lower post-exercise values compared with pre exercise, 
although these did not translate into significant changes in salivary kappa or lambda 
concentrations  or flow rates, FLC sum, FLC difference and Κ:λ ratio (Table 3) in response to 
exercise.  These results were mirrored for secretion rates and other saliva variables controlling for 
flow rate (Table 3).  The median % changes in salivary FLC concentrations and secretion rates are 
summarised in Table 5. Although not statistically significant, % reductions in FLC post-exercise 
were typically higher in response to the 1 h TT than 2 h of submaximal cycling.  
Serum  
No changes were observed in serum FLCs in response to exercise (Table 3).  Haematological 
measures were not assessed in this study; however, participants consumed water ad libitum during 
exercise in a temperature controlled environment (18–20°C), therefore any changes in plasma 
volume would be expected to be minor (< 5%) based on previous observations under similar 
conditions. 
 
 
III. The effects of an incremental submaximal treadmill test to 75% HRmax on free light chains in 
healthy older adults  
Saliva  
There was no significant effect of exercise on saliva flow rates in the older adult cohort (Table 4). 
There was a significant main effect of time for both kappa, F(2,104) = 23.12,  p < 0.001, η2 = 0.308 
and lambda, F(2,104) = 24.54,  p < 0.001, η2 = 0.321, FLC concentrations.  As shown in Figure 2, 
salivary FLC concentrations were significantly reduced post-exercise and 1 h post-exercise 
compared with pre-exercise in saliva.  Levels then significantly increased at 1 h post-exercise 
compared with immediately post-exercise.  The same response pattern was observed for FLC sum 
and difference: decreasing post-exercise, followed by an increase at 1 h, but remaining below pre-
15 
 
exercise values: F(2,104) = 24.22,  p < 0.001, η2 = 0.318 and F(2,104) = 19.63,  p < 0.001, η2 = 
0.274, respectively.  There was no significant effect of exercise on the Κ:λ ratio.  
Saliva secretion rates (Figure 3) followed the same response profile as concentration, with kappa 
(F(2,98) = 29.58  p < 0.001, η2 = 0.376) and lambda (F(2,98) = 33.56  p < 0.001, η2 = 0.406) 
secretion reducing post-exercise, followed by an increase at 1 h post-exercise.  Differences across 
all time points were also observed for FLC sum (F(2, 98) = 31.793  p < 0.001, η2 = 0.394) and FLC 
difference (F(2,98) = 19.51  p < 0.001, η2 = 0.285) when controlling for flow rate.  There was a 
significant difference in the Κ:λ ratio controlling for flow rate (F(2,98) = 4.84  p = 0.012, η2 = 0.090, 
Table 4), where the ratio significantly decrease post-exercise, followed by a significant  increase 1 
h post-exercise compared with immediately post; this recovery in the ratio was above pre-exercise 
levels.  Percentage changes in FLC in response to exercise for older adults are reported in Table 
5.  
Serum 
As shown in Figure 2, there were no significant effects of exercise on kappa or lambda FLC 
concentrations in serum, nor was there any impact of exercise on the serum FLC sum, difference 
or Κ:λ ratio (Table 4).  The median plasma volume reduction post-exercise was -3.9% and by 1 h 
post-exercise had increased above pre-exercise levels by a median of 3.7%.  Plasma volume 
increased by a median of 7.5% between immediately post- and 1 h post-exercise.  Following 
adjustment for plasma volume changes, there were still no significant effects of exercise on serum 
FLC. 
IV. Comparison of the effects of acute exercise on free light chains in young and older adults  
Table 5 summarises the % FLC changes in serum and saliva in response to exercise across 
studies. When comparing the degree of percentage change between studies, a significant 
difference was observed for the % change in lambda salivary FLC from pre- to post-exercise 
between the older adults and young adults who exercised at 60% VO2max for 2 h, F(2,78) = 4.31  
p = 0.017, η2 = 0.099.  There were no other significant differences % changes in response to 
exercise between studies.  
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DISCUSSION  
For the first time we have established reference ranges for FLCs in saliva for healthy individuals 
through application of newly developed highly sensitive ELISAs.  Previously it was not possible to 
reliably detect FLCs in saliva due to the sensitivity and technical limitations of existing 
commercially available assays.  The total sum of FLCs in saliva was typically < 1 mg/L for young 
and < 5 mg/L for older adults, which is below the lower range of other assays.  The lowest 
calibration point of FreeliteTM, the first and most widely used FLC assay, is typically 3 mg/L for 
kappa and 5 mg/L for lambda.  The precision around these concentrations has been accepted as 
being poor and the ‘gap’ in quantitation at the lower end of the assay has been highlighted 
previously (24, 29).  The development of these new highly sensitive FLC assays opens the door to 
improved detection and accuracy for a range of other biological specimens that characteristically 
have low concentrations of FLCs, such as cerebral spinal fluid and urine.  
Overall median concentrations of salivary kappa FLCs were 10-fold lower, and lambda FLCs 20-
fold lower compared with serum.  Interestingly, no significant correlations emerged between FLCs 
in saliva and serum for any parameters, with the exception of the FLC ratio and FLC difference. 
This suggests that the proportion and difference between FLC isotypes in saliva broadly reflects 
serum, but saliva may not be representative of individual kappa and lambda concentrations or total 
polyclonal FLC levels in serum.  Consequently, these data do not provide evidence that salivary 
FLC levels are able to identify those with higher/lower FLC levels in serum, but could be useful in 
detecting those with altered FLC ratios or large differences between isotypes.  This would be 
particularly applicable in plasma cell dyscrasias. Future research in disease populations is required 
to develop salivary FLC reference ranges in patients and explore the relationship between FLCs in 
serum and saliva to assess disease-specific utility.  
Identifying the source of FLCs in saliva was not examined as part of the present investigation; 
however, possible pathways have been highlighted by other studies involving salivary biomarkers.  
The predominant immunoglobulin in saliva is secretory IgA, which is secreted by local plasma cells 
and synthesised in dimeric form. Alternatively, IgG, and the majority of monomeric IgA, present in 
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saliva is derived from serum rather than local production; these likely enter the saliva through 
gingival cervices, via gingival crevicular fluid (GCF) (30, 31).  GCF is an oral fluid that consists of 
serum transudate and tissue exudates, and has been shown to include immunoglobulins (32).  
Other serum factors, such as hormones, can enter saliva via passive diffusion through cells or 
filtration mechanism between cells, depending on the size of the molecule (33).  As FLCs 
concentrations and secretion rates in saliva did not correlate well with serum levels, a proportion of 
FLCs in saliva may be a result of local production and/or dependent upon variable levels of 
periodontitis.  FLCs in saliva could be from serum or may reflect local production, or a combination 
of both these possibilities.  Further studies are required to determine the exact source and mode of 
entry of FLCs in saliva.  
Older adults demonstrated significantly higher levels of all FLC parameters in saliva compared with 
young adults.  Saliva flow rates were significantly lower in older adults compared to young adults. 
This is consistent with previous studies and has been proposed to be driven by medication use 
(28, 34), in fact, flow rate may not be affected by age in healthy individuals who are not taking 
medication (35).  In the present study, all findings withstood correction for chronic medication 
usage and when adjusting for flow rate all saliva parameters remained higher in the older adults, 
suggesting the observed age differences are not simply reflecting flow rate differences.  The 
pattern of elevated FLCs in the older cohort was not observed for serum, where higher lambda 
FLC levels were seen in the younger adults, resulting in a lower FLC ratio and higher FLC 
difference.  Although these findings were statistically significant, it should be noted that all 
participants had FLC levels and ratios within the normal range, and these age differences in serum 
are therefore unlikely to have any clinical implications.   
As age-related increases were observed across saliva indices rather than serum, these findings 
may be indicative of age specific changes at an oral level.  Physiological changes due to ageing 
have been hypothesised to result in salivary gland atrophy and in turn affect secretory capacity, 
although available evidence suggests that this postulation may not necessarily be true (36). The 
present study suggests that the concentration and secretion of FLCs is elevated rather than 
diminished with age; this may be due to oral factors related to ageing.  Ageing is associated with 
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higher rates of gum disease, decay and consequently tooth loss. In the UK, less than 10% of 
adults over 65 years of age have no signs of pocketing, calculus or bleeding (indicators of 
periodontal health) and only 1% of adults aged over 55 can be classified as having excellent oral 
health (37).  Nearly 50% of adults aged 65–74 display signs of gingivitis and 65% of 75–84 year 
olds have indications of more advanced periodontal disease (38).  Similarly, a large study in the 
US found that 64% of adults aged ≥ 65 had moderate or severe periodontitis (39).  Periodontitis is 
associated with low molecular weight serum proteins in the crevivular fluid, proportional to the 
degree of inflammation (40).  Low molecular weight proteins would encompass of FLCs rather than 
whole immunoglobulins.  The higher levels of salivary FLCs observed in the elderly cohort may 
reflect poorer overall oral health and accompanying greater degree of immune activation and 
inflammation compared with the young cohort.  Although no participants in the present study 
reported any specific dental problems or gum disease, underlying processes may be taking place 
that have not yet manifested with any noticeable signs to the individual, or may occur prior to the 
presentation of periodontal disease.  Broader ranges of FLCs were observed in older adults for 
saliva variables compared with young adults, suggesting a higher degree on inter-individual 
variability in this age group; this may reflect larger individual differences in oral health.  
Elevated salivary FLC levels in older individuals may have implications for wider aspects of health. 
The immune decline and dysregulation that occurs with ageing favours a pro-inflammatory profile, 
which is associated with various chronic diseases (41, 42).  Oral inflammation has been suggested 
to impact upon systemic inflammation, and consequently effect vital organs and contribute to or 
exacerbate inflammatory conditions (43); this concept is particularly important in the context of 
immunosenescence and age-related diseases.  Although FLCs have been implicated in immune 
and inflammatory processes, as this is the first study to explore salivary FLCs their specific roles 
within the oral environment is currently unknown.  Further, in the present sample all participants 
had serum FLC levels within the normal range and were in good health. It would be interesting to 
examine the relationship between salivary FLCs and serum FLCs in patients with periodontitis or 
chronic diseases where polyclonal FLCs may be elevated.  Alternatively, as evidence suggests 
that FLCs may have anti-viral properties (20), raised FLCs may also confer some degree of 
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protection against pathogens, such that having elevated levels may in fact be advantageous.  
Whole immunoglobulins were not measured as part of the present study; however, salivary IgA 
secretion rates have been shown to be significantly lower in elderly individuals and decrease with 
increasing age (34, 44).  The balance between secretory immunity and FLCs in saliva should be 
explored as part of future investigations. Further, repeated sampling across the day should also be 
carried out to determine if salivary FLCs exhibit diurnal variation and if time of day is a factor to 
consider when designing studies.  
In younger adults, 2 h of submaximal exercise resulted in modest reductions in salivary FLC 
concentrations and secretions rates immediately post-exercise. However, significant findings only 
emerged in relation to the FLC difference and Κ:λ ratio between post- and 1 h post-exercise; these 
were driven by slightly higher recovery of kappa FLC concentrations and secretions at 1 h relative 
to lambda FLCs.  For the 1 h TT, percentage reductions in salivary parameters post-exercise were 
greater than observed after 2 h of cycling, but no significant findings were observed for this 
exercise trial. In contrast, older adults demonstrated significant reductions in kappa and lambda 
FLC concentrations and secretion rates, in addition to sum, difference and ratio parameters, post-
exercise.  These variables then significantly increased 1 h post-exercise compared to immediately 
post-exercise, although generally remained significantly below pre-exercise values.  These findings 
suggest that salivary FLCs are significantly reduced after exercise in older adults, where only minor 
alterations occur in young individuals.   
Stimulation of the sympathetic nervous system can result in vasoconstriction of salivary glands.  
This, in addition to hyperventilation causing evaporation and dehydration during exercise, may lead 
to a decrease in saliva volume (45, 46).  Parasympathetic withdrawal is also thought to contribute 
significantly to the reduction in saliva flow rate with exercise (44). It may be that blood flow to the 
saliva glands during exercise is reduced to a greater extent in older adults.  However, given there 
was no significant effect of exercise on saliva flow rates, in either age group, and changes were 
also observed when variables were expressed as secretion rates, the mechanism responsible for 
the decrease in salivary FLCs does not appear to be linked to saliva volume.  These changes are 
also unlikely to reflect differences in exercise duration or intensity.  Older adults exercised for one 
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third or sixth of the time as the young adult cohorts, and although the maximum intensity was 
higher than the 2 h cycling bout, the TT exceeded 75% HRmax. Prolonged and intense exercise has 
been shown to decrease secretion of salivary IgA, which has been attributed to changes in 
transport into the saliva, rather than changes in local plasma cell activation and immunoglobulin 
synthesis (47).  It is likely that this is also the case for FLCs due to the transient nature of exercise-
induced changes, and the mechanisms of FLC transport into the saliva are reduced in response to 
exercise, without any significant accompanying change in volume.  As the roles of salivary FLCs 
are yet to be determined, the implications of a reduction in FLCs post-exercise are unclear at 
present, nor if acute changes translate into altered resting levels as a result of exercise training.   
Serum FLCs did not change in response to exercise in either age group.  This is consistent with 
findings in elderly individuals in relation to endurance walking (22).  In contrast, increases in FLCs, 
resulting in minor elevations in FLC sum and Κ:λ ratio, have been observed after marathon running 
(24).  It may be that only high intensity exercise of a sufficiently prolonged nature is capable of 
eliciting perturbations in serum FLC parameters. Including the present study, only three 
investigations into FLCs and exercise have taken place to date.  Further studies are required to 
fully characterise the FLC response to acute exercise, including resistance exercise.  
Conclusions  
We have generated reference ranges for FLCs in saliva in healthy individuals.  Polyclonal FLCs in 
serum have been shown to be able to identify and monitor disease in a range of conditions and be 
prognostic of mortality in the general population.  The ability to reliably assess FLCs in saliva and 
the reference ranges provided will potentially broaden the use of this biomarker in healthy and 
clinical populations.  We have demonstrated that older adults have higher salivary FLC parameters 
compared with young adults.  This may be important in the context of inflammatory process and 
diseases associated with ageing.  Additional research is required to explore connections between 
serum and saliva FLCs in disease and understand the biological roles of salivary FLCs.  Exercise 
did not affect serum FLCs, but significantly reduced salivary FLCs in older adults.  These changes 
appear to be transient and FLC concentrations and secretion rates began to recover at 1 h post-
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exercise, although remained below pre-exercise values.  Future studies are needed to appreciate 
the relationship between FLCs and acute exercise and chronic exercise training.  Given what we 
already know about serum FLCs and their diverse applications as a biomarker, salivary FLCs have 
a range of exciting prospects within aspects of ageing, disease and exercise immunology research. 
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Figure 1. Salivary kappa (A) and lambda (B) free light chain (FLC) secretion rates and the 
kappa:lambda ratio controlling for flow rate (C) in young and older adults. Boxes represent the 25–
75th percentile, with the line indicating the median, and whiskers show the 10–90th percentile.   
∗ Significantly higher FLC secretion rate and kappa:lambda ratio in the older adults compared with 
the young adults, p < 0.001 
 
 
 
 
 
  
Figure 2. Kappa (A) and lambda (B) free light chain (FLC) concentrations in serum and saliva in 
response to submaximal exercise in older adults 
∗ Kappa (A) and lambda (B) FLC concentrations were significantly reduced post-exercise and 1 h 
post-exercise compared with pre-exercise in saliva, p < 0.001; † Kappa and lambda FLC 
concentrations increased 1 h post-exercise compared with immediately post-exercise in saliva,      
p < 0.05. Serum FLC levels did not change in response to exercise. Values are means ± SEM 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3. Salivary kappa (A) and lambda (B) free light chain (FLC) secretion rates in response to 
submaximal exercise in older adults 
∗ Kappa (A) and lambda (B) FLC secretion rates were significantly reduced post-exercise              
(p < 0.001) and 1 h post-exercise (p < 0.01) compared with pre-exercise in saliva; † Kappa and 
lambda FLC secretion rates increased 1 h post-exercise compared with immediately post-exercise, 
p < 0.001. Values are means ± SEM 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Participant characteristics and free light chain (FLC) parameters in saliva and serum in 
healthy young and older adults. All values are median (5–95 percentile) unless stated 
 Young adults  
(N = 88) 
Older adults  
(N = 53) 
F η2 
Age (years), median (range)  24 (18–36)*** 67 (60–80) 2988.15 .957 
BMI (kg/m2), median (range) 
 
23.15 (18.30–28.70)* 23.90 (19.10–33.26) 6.14 .064 
Males, n (%)  63 (72%) 30 (60%)   
Saliva flow rate (mL/min) 0.44 (0.12–0.92)** 0.31 (0.10–0.80) 8.67 .059 
Saliva concentrations (mg/L)     
Kappa  0.45 (0.004–3.45)*** 3.91 (0.75–19.65) 99.10 .416 
Lambda  0.30 (0.08–1.54)*** 1.00 (0.02–4.50) 55.17 .284 
FLC sum  0.80 (0.11–4.84)*** 4.80 (1.06–23.49) 113.48 .449 
FLC difference 0.03 (-0.43–1.89)*** 2.92 (0.09–15.80) 148.94 .517 
Κ:λ ratio  1.13 (0.05–4.68)*** 4.20 (1.22–9.37) 65.48 .320 
Saliva parameters controlling 
for flow rate (µg/min)  
    
Kappa secretion rate 0.18 (0.003–1.35)*** 1.38 (0.16–5.67) 71.45 .340 
Lambda secretion rate  0.14 (0.03–0.68)*** 0.35 (0.07–1.24) 25.61 .156 
FLC sum   0.38 (0.04–1.91)*** 1.86 (0.03–4.79) 74.04 .348 
FLC difference   0.01 (-0.17–0.86)*** 1.03 (0.03–4.79) 117.06 .457 
Κ:λ ratio 0.47 (0.02–3.01)*** 1.40 (0.25–5.69) 26.81 .162 
Serum FLC concentration (mg/L)       n = 38 n = 40   
Kappa  10.41 (7.41–14.35) 11.36 (5.11–16.70) 0.50 .006 
Lambda   13.16 (8.61–20.51)** 9.50 (5.90–18.81) 8.79 .104 
FLC sum  23.62 (16.91–33.79) 20.73 (10.68–35.38) 2.29 .029 
FLC difference  -2.58 (-7.21–1.87)*** 0.77 (-4.02–4.20) 23.65 .235 
Κ:λ ratio 0.81 (0.58–1.29)*** 1.07 (0.77–1.52) 27.83 .268 
                                                                                                                                                      
Significant differences between age groups are indicated by *** p < 0.001, ** p < 0.01, * p < 0.05 
Degrees of freedom for saliva parameters F(1,139) and F(1,76) for serum  
 
 
 
Table 2. Salivary free light chain (FLC) responses to 2 h cycling at 60% VO2max in healthy 
exercise-trained young men  
Median (range)  Pre-exercise Post-exercise 1 h post-exercise 
Saliva flow rate (mL/min)  0.40 (0.11–0.84) 
 
0.30 (0.07–0.78) 0.31 (0.11–0.77) 
Saliva concentrations 
(mg/L) 
 
Kappa  0.41 (0.004–1.96) 0.20 (0.004–2.19) 0.38 (0.004–3.49) 
Lambda  0.25 (0.03–1.46) 0.32 (0.07–0.97) 0.40 (0.003–2.11) 
FLC sum  0.81 (0.03–2.75) 0.55 (0.10–3.05) 0.75 (0.01–4.99) 
FLC difference -0.02 (-0.82–1.38) -0.07 (-0.71–1.33) 0.02 (-0.37–1.99)* 
Κ:λ ratio   0.83 (0.03–4.29) 0.66 (0.02–2.54) 1.15 (0.02–3.39)* 
Saliva parameters 
controlling for flow rate 
(µg/min)  
 
Kappa secretion 0.12 (0.001–0.69) 0.06 (0.001–0.54) 0.12 (0.001–1.175) 
Lambda secretion  0.14 (0.02–0.40) 0.08 (0.02–0.29) 0.12 (0.001–0.66) 
FLC sum   0.32 (0.02–1.02) 0.13 (0.02–0.74) 0.23 (0.002–1.62) 
FLC difference   -0.01 (-0.26–0.53) -0.01 (-0.21–0.32) 0.01 (-0.12–0.73)* 
Κ:λ ratio 0.28 (0.001–3.03) 
 
0.13 (0.00–0.90) 0.36 (0.01–1.83)** 
                                                                                                                                                             
Significantly different to post-exercise indicated by * p < 0.05, ** p < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Free light chain (FLC) saliva and serum parameters in response to an all-out 1 h cycling 
time trial in young, well-trained, male cyclists   
Median (range)  Pre-exercise Post-exercise 
Saliva flow rate 
(mL/min)  
 
0.51 (0.28–1.25) 0.48 (0.24–0.83) 
 
Saliva concentrations 
(mg/L) 
 
Kappa 1.19 (0.13–4.07) 
 
0.74 (0.14–1.51) 
Lambda 0.60 (0.14–3.65) 0.33 (0.22–2.03) 
FLC sum  1.99 (0.27–7.07) 
 
1.23 (0.48–3.54) 
FLC difference 0.37(-0.23–2.90)  0.03 (-0.81–1.27) 
 
Κ:λ ratio 2.70 (0.97–3.91) 1.09 (0.15–6.83) 
 
Saliva parameters 
controlling for flow 
rate (µg/min) 
 
Kappa secretion  0.80 (0.17–1.60) 
 
0.41 (0.03–0.71) 
 
Lambda secretion 0.37 (0.08–1.04) 0.21 (0.07–0.88) 
FLC sum   1.26 (0.27–2.07) 0.55 (0.26–1.52) 
FLC difference    0.25 (-0.08–1.14)  0.02 (-0.23–0.42) 
 
Κ:λ ratio 1.30 (0.27–3.25) 0.75 (0.04–2.26) 
Serum concentration 
(mg/L) 
 
Kappa  10.24 (7.91–12.29) 10.68 (7.28–13.96) 
Lambda  13.04 (10.44–17.25) 12.89 (8.45–16.74) 
FLC sum  23.38 (18.64–28.44) 24.26 (15.74–29.86) 
FLC difference -2.37 (-6.06–0.96) -2.53 (-5.87–0.02) 
Κ:λ ratio 0.75 (0.58–1.09) 
 
0.76 (0.65–1.00) 
                                                                                                                                                                              
 
 
 
 
 
 Table 4. Free light chain (FLC) responses to an incremental submaximal treadmill test to 75% 
HRmax in healthy older adults  
Median (5–95th percentile)  Pre-exercise Post-exercise 1 h post-exercise 
Saliva flow rate (mL/min)  0.31 (0.09–0.80) 0.29 (0.10–0.86)* 0.32 (0.11–0.90) 
Saliva concentrations (mg/L) 
FLC sum  4.80 (1.06–23.49) 2.84 (0.44–17.17) 3.83 (0.61–16.97)*** ††† 
FLC difference 2.92 (0.9–15.80) 1.72 (-0.37 –13.49)*** 2.14 (0.11–12.77)*** ††† 
FLC ratio  4.20 (1.23–9.37) 4.16 (0.37–9.05) 4.29(1.14–8.57) 
Saliva parameters controlling for flow rate (µg/min)  
FLC sum   1.86 (0.28–6.67) 0.65 (0.08–4.44)*** 1.11 (0.22–6.34)*** ††† 
FLC difference   1.03 (0.02–4.80) 0.40 (-0.03–3.12)*** 0.65 (-0.002–4.36)*** ††† 
FLC ratio  1.39 (0.25–5.69) 1.01 (0.05–4.62)* 1.45 (0.19–4.97)† 
Serum concentrations (mg/L)    
FLC sum  20.73 (10.68–35.38) 20.98 (11.00–34.88) 20.42–35.60) 
FLC difference 0.77 (-4.02–4.20) 0.63 (-3.87–4.30) 1.15 (-3.87–4.41) 
Κ:λ ratio 1.07 (0.71–1.52) 1.07 (0.70–1.43) 1.13 (0.71–1.45) 
                                                                                                                                                                                    
∗ Significantly different to pre-exercise; † significantly different to post-exercise 
*** and ††† p < 0.001; * and † p < 0.05 
 
 
 
 
 
 
 
 
 
 
 
Table 5.  Summary of median percentage changes in free light chain parameters in serum and 
saliva in response to acute exercise in young and older adults  
 Young adults  Older adults  
 Maximal exercise:  
1 h all-out cycling 
time trial  
Submaximal exercise: 
2 h cycling at 60% 
VO2max 
Submaximal treadmill 
test to 75% HRmax 
 % pre–post % pre–post %pre–1 h 
post 
%pre–post %pre–1 h 
post 
Saliva concentration  
Kappa  -33.9 -9.6 -6.0 -50.6 -27.9 
Lambda  -6.2 5.6 -3.9 -46.3* -37.6 
Saliva Secretion  
Kappa  -34.0 -29.8 -10.4 -59.0 -26.8 
Lambda  -8.2 -12.0 -28.8 -53.5 -31.0 
Serum concentration  
Kappa  2.4   1.3 0.7 
Lambda 0.6   0.3 -2.3 
                                                                                                                                                             
* Significantly different to young adults submaximal exercise pre-post change value, p < 0.05 
 
 
 
 
 
